HOTH (Hoth Therapeutics, Inc.) Stock Financials & Earnings

HOTHHoth Therapeutics, Inc.

Mkt Cap$13M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$12M

EPS (TTM)-$1.16

Free Cash Flow (TTM)-$10M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q4 2025 · Mar 27

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$3M
Q1 23	$0	$0	-$2M
Q2 23	$0	$0	-$2M
Q3 23	$0	$0	-$2M
Q4 23	$0	$0	-$2M
Q1 24	$0	$0	-$2M
Q2 24	$0	$0	-$2M
Q3 24	$0	$0	-$2M
Q4 24	$0	$0	-$2M
Q1 25	$0	$0	-$3M
Q2 25	$0	$0	-$2M
Q3 25	$0	$0	-$4M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$1M	—	—	$2M
Q1 23	$939K	$1M	$15K	—
Q2 23	$652K	$1M	$8K	—
Q3 23	$974K	$1M	$7K	—
Q4 23	$915K	—	—	$783K
Q1 24	$572K	$2M	$13K	—
Q2 24	$566K	$1M	—	—
Q3 24	$898K	$1M	—	—
Q4 24	$1M	$1M	$13K	—
Q1 25	$2M	$2M	$13K	—
Q2 25	$1M	$1M	—	—
Q3 25	$2M	—	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$6M	$209K	$7M
Q1 23	$13M	$191K	$13M
Q2 23	$12M	$25K	$12M
Q3 23	$12M	$25K	$12M
Q4 23	$9M	$0	$9M
Q1 24	$8M	$0	$8M
Q2 24	$10M	$0	$10M
Q3 24	$8M	$0	$8M
Q4 24	$7M	$0	$7M
Q1 25	$11M	$0	$11M
Q2 25	$9M	$0	$9M
Q3 25	$8M	$0	$8M

Shares Outstanding

Revenue Per Employee

Revenue / Employee